Physician profile
Kimberly Bennett
NPI 1376084541
$941.67
in general payments reported to CMS, 2019-2025
14 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $148 · 2024: $436 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $154.52 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.73 | 2022-2025 | Jardiance |
| Davol INC. | $90.91 | 2025 | Phasix Mesh |
| Csl Behring | $80.20 | 2023-2024 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $68.58 | 2023-2024 | Camzyos, Eliquis |
| Shionogi INC | $66.76 | 2022-2025 | Fetroja |
| Janssen Pharmaceuticals, INC | $65.06 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $63.12 | 2022 | |
| Paratek Pharmaceuticals, INC. | $60.10 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $55.39 | 2023-2024 | Dificid, Zerbaxa |
| Alexion Pharmaceuticals, INC. | $44.04 | 2024 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.65 | 2022-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $32.17 | 2025 | Vowst |
| Vertex Pharmaceuticals Incorporated | $17.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.